Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AdaptHealth (AHCO)

AdaptHealth Q3 revenue rises 0.2% to $805.9 million; 2024 outlook lowered

Mixed Impact 4 of 5 earnings Written later

AdaptHealth reported third-quarter 2024 net revenue of $805.9 million, up 0.2%, and net income attributable to the company of $22.9 million, compared with a net loss of $454.1 million a year earlier. The company lowered its 2024 net revenue and adjusted EBITDA guidance while raising its free cash flow guidance, so results and outlook point in different directions for shareholders.

Key points

  • Net revenue was $805.9 million versus $804.0 million, and adjusted EBITDA was $164.3 million versus $161.2 million, up 1.9%.
  • Net income attributable to AdaptHealth was $22.9 million, compared with a net loss of $454.1 million in the prior-year quarter, which included a $511.9 million goodwill impairment.
  • 2024 net revenue guidance was lowered to $3.220 billion to $3.260 billion from $3.255 billion to $3.315 billion.
  • 2024 adjusted EBITDA guidance was lowered to $655 million to $675 million from $660 million to $700 million; free cash flow guidance was raised to $175 million to $195 million from $160 million to $180 million.

The filing

CompanyAdaptHealth (AHCO)
Form8-K, current report
Filed with the SECNov 5, 2024, 7:36 AM ET
Accession number0001628280-24-045113

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.